Molecular Templates Inc
0.0 %
-96.04 %
Yet to be announced
Company Overview
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The company's proprietary technology platform, called Engineered Toxin Bodies (ETBs), is designed to generate novel drugs with unique mechanisms of action for cancer and other serious diseases.
Revenue Sources
Based on the company's financial statements and business model, their revenue primarily comes from research and development collaborations and licensing agreements in the biotechnology sector. The company is focused on developing therapeutic treatments, which is a halal business activity. There is no evidence of revenue from prohibited sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $572,000 | $8.91m | - | $38,000 | 0.00% | 0.43% |
| March 31, 2024 | $11.09m | $11.17m | - | $31,000 | 0.00% | 0.28% |
| Dec. 31, 2023 | $7.02m | $12.43m | - | $39,000 | 0.00% | 0.31% |
| Sept. 30, 2023 | $6.8m | $12.04m | - | $31,000 | 0.00% | 0.26% |
The company is still in its clinical development phase and not yet in a mature operational stage. The interest expenses over the past four quarters have been minimal relative to total expenses. Given the company's pre-revenue research and development stage, we do not consider the interest component to be material to their business model.
Operational Ethics
Based on available information from SEC filings and company disclosures, there is no evidence of any significant ongoing associations with entities involved in human rights violations. The company's operations appear to be primarily based in the United States with no significant ties to Israel or the Chinese Communist Party.
Login to join the discussion